P02-019 - Detection of risk factors for AA-amyloidosis
Shorin Nemeth, Laura Piera Obici, Sylvie Grandemange, Helen Jane Lachmann, Christian Oberkanins
Abstract
Open-access reader
Shorin Nemeth, Laura Piera Obici, Sylvie Grandemange, Helen Jane Lachmann, Christian Oberkanins
Abstract
Open-access reader
Systemic reactive (AA) amyloidosis represents the most important complication within TNF receptor associated periodic syndrome (TRAPS), familial Mediterranean fever (FMF) and other autoinflammatory syndromes, progressively leading to endstage renal failure. The homozygous condition of the serum amyloid A (SAA) variant SAA1.1 is significantly associated with the occurrence of AA amyloidosis in TRAPS patients. Likewise in FMF patients the MEFV mutation c.2080A>G (M694V) correlates with amyloidosis and the SAA1.1/SAA1.1 genotype increases clinical severity (age at disease onset, amyloidosis, arthritis).
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Systemic reactive (AA) amyloidosis represents the most important complication within TNF receptor associated periodic syndrome (TRAPS), familial Mediterranean fever (FMF) and other autoinflammatory syndromes, progressively leading to endstage renal failure. The homozygous condition of the serum amyloid A (SAA) variant SAA1.1 is significantly associated with the occurrence of AA amyloidosis in TRAPS patients. Likewise in FMF patients the MEFV mutation c.2080A>G (M694V) correlates with amyloidosis and the SAA1.1/SAA1.1 genotype increases clinical severity (age at disease onset, amyloidosis, arthritis).
Key concepts: Familial Mediterranean fever, Medicine, Amyloidosis, AA amyloidosis, MEFV, Serum amyloid A, Internal medicine, Rheumatology